Novartis (NVS)
(Delayed Data from NYSE)
$110.32 USD
+0.39 (0.35%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $110.30 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.32 USD
+0.39 (0.35%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $110.30 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Zacks News
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
by Zacks Equity Research
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
by Zacks Equity Research
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
by Zacks Equity Research
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Novartis (NVS) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
by Zacks Equity Research
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
by Zacks Equity Research
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
by Zacks Equity Research
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
by Zacks Equity Research
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.